SCHEMBL18220188

SCHEMBL18220188

COCCNC(=O)/C(C#N)=C/c1ccc(-c2ccc3cc(N4CCN(C)CC4)ccc3c2)n1C

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
APP P05067 3/20 0.51
RXFP1 Q9HBX9 3/20 0.49
KMT2A Q03164 7/20 0.46
MEN1 O00255 5/20 0.46
ALDH1A1 P00352 3/20 0.46
LMNA P02545 3/20 0.46
HPGD P15428 2/20 0.46
MITF O75030 1/20 0.46
MAPK1 P28482 1/20 0.46
MDM2 Q00987 1/20 0.46
SMN1; SMN2 Q16637 1/20 0.46
KDM4E B2RXH2 4/20 0.45
MAPT P10636 2/20 0.45
NPC1 O15118 1/20 0.45
NFKB1 P19838 1/20 0.45
RAB9A P51151 1/20 0.45
NFKB2 Q00653 1/20 0.45
RELA Q04206 1/20 0.45
ATM Q13315 1/20 0.44
USP2 O75604 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18220184 0.93 APP (0.50) APPRXFP1KMT2AMEN1ALDH1A1
SCHEMBL19293983 0.92 APP (0.46) APPRXFP1KMT2AMEN1ALDH1A1
SCHEMBL18220192 0.92 KMT2A (0.55) APPRXFP1KMT2AMEN1ALDH1A1
SCHEMBL23134975 0.89 APP (0.42) APPRXFP1KMT2AMEN1ALDH1A1
SCHEMBL17099878 0.89 APP (0.55) APPRXFP1KMT2AMEN1ALDH1A1
SCHEMBL17099870 0.89 APP (0.55) APPRXFP1KMT2AMEN1ALDH1A1
SCHEMBL24075821 0.89 APP (0.55) APPRXFP1KMT2AMEN1ALDH1A1
SCHEMBL17099866 0.89 APP (0.55) APPRXFP1KMT2AMEN1ALDH1A1
SCHEMBL25610089 0.87 APP (0.50) APPRXFP1KMT2AMEN1ALDH1A1
SCHEMBL24068143 0.85 APP (0.45) APPRXFP1KMT2AMEN1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240208916-A1 AMYLOID TARGETING AGENTS AND METHODS OF USING THE SAME Amydis, Inc. 2024-06-27 US disclosed
US-11718596-B2 Amyloid targeting agents and methods of using the same THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2023-08-08 US disclosed
US-10934264-B2 Amyloid targeting agents and methods of using the same THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2021-03-02 US disclosed
US-20200123118-A1 AMYLOID TARGETING AGENTS AND METHODS OF USING THE SAME THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 2020-04-23 US disclosed
US-10005745-B2 Amyloid targeting agents and methods of using the same THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2018-06-26 US disclosed
US-20170248616-A1 IN VITRO COMPOSITIONS COMPRISING HUMAN SAMPLE AND AMYLOID TARGETING AGENT Amydis, Inc. 2017-08-31 US disclosed
US-20160326126-A1 AMYLOID TARGETING AGENTS AND METHODS OF USING THE SAME Amydis, Inc. 2016-11-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11718596-B2 Amyloid targeting agents and methods of using the same APP, CRYAA, APBA1 APP 1/4885RXFP1 4279/4885KMT2A 4649/4885
US-20200123118-A1 AMYLOID TARGETING AGENTS AND METHODS OF USING THE SAME APP, CRYAA, APBA1 APP 1/4885RXFP1 4279/4885KMT2A 4649/4885
US-20240208916-A1 AMYLOID TARGETING AGENTS AND METHODS OF USING THE SAME APP, CRYAA, APBA1 APP 1/4885RXFP1 4279/4885KMT2A 4649/4885
US-20160326126-A1 AMYLOID TARGETING AGENTS AND METHODS OF USING THE SAME APP, APBA1, CRYAA APP 1/4885RXFP1 4325/4885KMT2A 4621/4885
US-10934264-B2 Amyloid targeting agents and methods of using the same APP, CRYAA, APBA1 APP 1/4885RXFP1 4279/4885KMT2A 4649/4885
US-10005745-B2 Amyloid targeting agents and methods of using the same APP, APBA1, CRYAA APP 1/4885RXFP1 4325/4885KMT2A 4621/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.